Allergan announced its intent to combine with AbbVie to create the 4th largest global pharmaceutical company in the world. AbbVie is a highly focused research-driven biopharmaceutical company that takes on the toughest health challenges. They do more than treat diseases—they aim to make a remarkable impact on people’s lives.
Brad McRae, Ph.D., director of pharmacology, immunology discovery at AbbVie, is spending a lot of time looking at that environment of bacteria in stomach.
In a healthier gut, the bacteria metabolize dietary fiber to short chain fatty acids. Those fatty acids then communicate with epithelial cells and the immune system in your gut. In people with obesity, microbial diversity in the gut is reduced, leading to an imbalance called dysbiosis. The reduction in diversity in the gut microbiome negatively impacts immune regulation, as well as the function of the thin tissue that covers internal organs which can allow for more disease-causing bacteria to overgrow. “By looking at the microbiome of patients who are overweight, who then become obese could give us a better understanding of the role of the microbiome in this process,” McRae says. Identifying the change in gut physiology could be a game-changer towards health and wellness. We here at Laser Aesthetics Body and Wellness are committed to seek the best research for our patients. Please give us a call at 901-388-8887 for a free consultation.